多参数MRI时代的前列腺癌局灶治疗:选项与结局综述
本综述回顾了MRI引导治疗时代的英文临床试验文献,评估高强度聚焦超声、经尿道超声消融、局灶激光消融、局灶冷冻治疗、不可逆电穿孔和光动力疗法等局灶治疗。各技术复发率低至中等(0-51%),免于根治治疗率46-98%,勃起功能障碍0-44%,尿失禁0-12%。目前无任何学会指南推荐某一局灶治疗,随机对照试验正在进行中。
要点
- 各局灶治疗技术复发率0-51%,免于根治治疗率46-98%,功能结局因技术而异。
- 勃起功能障碍率0-44%,尿失禁率0-12%,比较研究时需注意患者选择的影响。
- 目前无学会指南推荐任何单一局灶治疗,随机对照试验正在进行。
核心结论
- 对于MRI可见的局限性前列腺癌,早期临床试验数据显示局灶治疗可提供良好至中等的癌症控制,且副作用谱优于全腺体治疗。
- 早期数据提示这些技术可能在经过良好选择的患者人群中提供充分的癌症控制,但需要更长期随访数据评估早期结局的持久性。
研究设计与样本
- 综述了所有评估局限性前列腺癌各种局灶治疗的英文临床试验文献。
- 文献检索限于MRI引导治疗现代时代的研究,因为假设MRI可改善肿瘤定位和靶向。
主要发现
- 识别出多种局灶治疗技术,包括高强度聚焦超声、经尿道超声消融、局灶激光消融、局灶冷冻治疗、不可逆电穿孔和光动力疗法。
- 所有技术的复发率低至中等(0-51%),免于根治治疗率高度可变(46-98%)。
- 勃起功能障碍率一般为0-44%,尿失禁率一般为0-12%,不同局灶治疗模式间存在差异。
关键数值与推荐
- 原发结局为治疗后无癌率、野内/野外复发率和转为根治治疗率;次要结局为功能状态和不良事件。
- 比较研究时应谨慎,因为结局与患者选择密切相关。
- 目前无学会指南推荐任何单一局灶治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 当前研究未对技术间进行头对头比较。
- 需要更长期随访数据评估早期结局的持久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The goal of prostate cancer focal therapy is to achieve oncologic control while reducing the rate of adverse events associated with whole-gland treatments. Numerous focal therapy modalities are currently available with early data demonstrating highly variable rates of cancer control and preservation of sexual/urinary function. METHODS: All English language clinical trial publications evaluating various focal therapies for localized prostate cancer were reviewed. The literature search was limited to studies from the modern era of MRI-guided treatment, as MRI is hypothesized to improve tumor localization and targeting. Primary outcomes were post-treatment cancer-free rates, in-field/out-of-field recurrence rates, and rates of conversion to radical therapy. Secondary outcomes were related to functional status and adverse events. RESULTS: Numerous focal therapies were identified with clinical data including high-intensity focused ultrasound, transurethral ultrasound ablation, focal laser ablation, focal cryotherapy, irreversible electroporation, and photodynamic therapy. Recurrence rates among all technologies were low to moderate (0-51%) and rates of freedom from radical treatment were highly variable (46-98%). Rates of erectile dysfunction and incontinence generally ranged from 0 to 44% and 0 to 12%, respectively, with variability between focal therapy modalities. Caution should be exercised when comparing studies as outcomes are strongly associated with patient selection. No individual focal therapy is currently recommended by society guidelines. Randomized controlled trials are ongoing in search of a standard of care. CONCLUSION: For localized MRI-visible prostate cancer, early clinical trial data demonstrate that focal therapy can provide good to moderate cancer control while having preferable side effect profiles compared to whole-gland treatments. While current studies do not make head-to-head comparisons between technologies, early data suggest a potential for these technologies to provide adequate cancer control in a well-selected patient population. The oncologic outcomes of some focal therapies appear promising; however, longer-term follow-up data are needed to assess the durability of early outcomes.
引用
- Heard JR, Naser-Tavakolian A, Nazmifar M, et al. Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes. Prostate Cancer Prostatic Dis. 2022. PMID: 35246609. doi:10.1038/s41391-022-00501-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。